Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind’s AlphaFold breakthrough, the company is ...

Under the agreement, Isomorphic is also eligible to receive up to $1.7bn in “performance-based milestones.” The company also signed a similar collaboration with Swiss biotech Novartis.

Isomorphic Labs, Google’s A.I. Drug Business, Raises $600 Million The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital as ...

Isomorphic Labs, an Alphabet-backed AI biotech firm, raised $600M to boost its AI drug design engine, expand clinical programs, and accelerate disease research.

> Isomorphic Labs is preparing to launch human trials of AI-designed drugs. > Mission: faster, cheaper, more accurate drug discovery using AI. AI will make the world a better place.

Isomorphic’s deals come as Google faces fierce competition on the development of AI software from the likes of Microsoft-backed OpenAI and smaller start-ups such as Anthropic and Cohere.

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised external capital for the first time. The $600 million round was led by Thrive Capital ...